Jena, Germany - InflaRx N.V., a leading biopharmaceutical company focused on developing anti-inflammatory treatments for the complement system, has successfully concluded its underwritten offering of 75,000,000 ordinary shares at $2.00 per share. The total gross earnings from this offering amounted to $150 million, excluding underwriting fees and other associated costs.